Seminars in Nuclear Medicine
Volume 32, Issue 2 , Pages 141-147 , April 2002

Receptor-mediated radiotherapy with 90Y-DOTA-DPhe1-Tyr3-octreotide: The experience of the european institute of oncology group

References 

  1. Krulich L, Dhariwal AP, McCann SM. Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology. 1968;83:783–790
  2. Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 1973;79:77–79
  3. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716–731
  4. Lamberts SWJ. Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med. 1990;323:1246–1249
  5. Reubi JC, Horisberger U, Laissue JA. High density of somatostatin receptors in veins surrounding human cancer tissue: Role in tumor-host interactions?. Int J Cancer. 1994;56:681–688
  6. Reubi JC, Schaer JC, Laissue JA, et al. Somatostatin receptors and theirs subtypes in human tumors and in peritumoral vessels. Metabolism Clin Exp. 1996;45(suppl 1):39–41
  7. Mc Carty KE, Woltering EA, Antony LB. In situ radiotherapy with 111In-pentetreotide. Q J Nucl Med. 2000;44:88–95
  8. Heppeler A, Froidevaux S, Eberle AN, et al. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem. 2000;7:971–994
  9. Harrison A, Walker CA, Parker D, et al. The in vivo release of 90Y from cyclic and acyclic ligand-antibody conjugates. Nucl Med Biol. 1991;18:469–476
  10. Moi MK, Meares CF. The peptide way to macrocyclic bifunctional chelating agents: Synthesis of 2-(p-nitroben-zyl)-1,4,7,10-tetraazacyclododecane-N,N′,N′',N′''-tetra-acetic acid and study of its Yttrium(III) complex. J Am Chem Soc. 1988;110:6266–6267
  11. Deshpande SV, DeNardo SJ, Kukis DL, et al. Yttrium-90-labeled monoclonal antibody for therapy: Labeling by a new macrocyclic bifunctional chelating agent. J Nucl Med. 1990;31:473–479
  12. Heppeler A, Froidevaux S, Mäcke HR, et al. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy. Chem Eur J. 1999;5:1974–1981
  13. Otte A, Jermann E, Béhé M, et al. DOTATOC-a new powerful tool for receptor-mediated radionuclide therapy. Eur J Nucl Med. 1997;24:792–795
  14. Paganelli G, Zoboli S, Cremonesi M, et al. Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide: preliminary report in cancer patients. Cancer Biother Radiopharm. 1999;14:477–483
  15. Reubi JC, Schär JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273–282
  16. de Jong M, Bakker WH, Krenning EP, et al. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0, D-Phe1, Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med. 1997;24:368–371
  17. de Jong M, Bakker WH, Breeman WA, et al. Pre-clinical comparison of [DTPA0,Tyr3] octreotide and [DOTA0,D-Phe1,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Int J Cancer. 1998;75:406–411
  18. Cremonesi M, Ferrari M, Zoboli S, et al. Biokinetics and dosimetry in patients administered with 111In-DOTA-Tyr3-octreotide: Implications for internal radiotherapy with 90Y-DOTATOC. Eur J Nucl Med. 1999;26:877–886
  19. Bakker WH, Albert R, Bruns C, et al. [111In-DTPA-D-Phe1] octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor — positive tumours: Synthesis, radiolabelling and in vitro validation. Life Sci. 1991;49:1583–1591
  20. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47:207–214
  21. Krenning EP, Kooij PPM, Bakker WH, et al. Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history. Ann N Y Acad Sci. 1994;733:496–506
  22. Krenning EP, De Jong M, Kooij PPM, et al. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol. 1999;10(suppl 2):23–29
  23. Stolz B, Weckbecker G, Smith-Jones PM, et al. The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-D-Phe1,Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours. Eur J Nucl Med. 1998;26:668–674
  24. Otte A, Mueller-Brand J, Dellas S, et al. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet. 1998;351:417–418
  25. Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC: First clinical results. Eur J Nucl Med. 1999;26:1439–1447
  26. 111P Valkema R, Jamar F, Jonard P, et al. Targeted radiotherapy with 90Y-DOTA-Tyr3-octreotide (90Y-SMT487; Octreother ™): A phase I study. J Nucl Med. 2000;41:
  27. Rosch F, Herzog H, Stolz B, et al. Uptake kinetics of the somatostatin receptor ligand [86Y]DOTA-D-Phe1-Tyr3-octreotide ([86Y]SMT487) using positron emission tomography in non-human primates and calculation of radiation doses of the 90Y-labelled analogue. Eur J Nucl Med. 1999;26:358–366
  28. 246P Cremonesi M, Ferrari M, Bodei L, et al. Renal protection in radionuclide therapy with 90Y-DOTATOC: Dosimetric evaluations. J Nucl Med. 2001;42:
  29. Kwekkeboom DJ, Bakker WH, Kooij PPM, et al. [177Lu-DOTAo,Tyr3]octreotate: Comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med. 2001;28:1319–1355

1 Supported by grants of the Italian association for Cancer Research (AIRC) and Consiglio Nazionale delle Ricerche (CNR-MIUR) PS Oncologia.

PII: S0001-2998(02)80032-0

doi: 10.1053/snuc.2002.31563

Seminars in Nuclear Medicine
Volume 32, Issue 2 , Pages 141-147 , April 2002

Article Tools